Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proteasome subunit beta type-11 (PSMB11/beta5t) is a specialized catalytic subunit incorporated in the thymoproteasome, a variant proteasome found exclusively in cortical thymic epithelial cells. Beta5t uniquely modulates the proteolytic activity of the complex, lowering chymotrypsin-like activity compared to conventional beta5 subunits. This produces a distinct set of self-peptides essential for the positive selection of CD8+ T cells, critical for proper immune system development. In clinical pathology, beta5t serves as a highly specific marker for cortical thymic epithelial cells and is pivotal in distinguishing thymoma subtypes from thymic carcinomas. To date, it is not an established target for approved drugs, but its role as a diagnostic biomarker in thymic neoplasia is well recognized.
Not directly targeted by drugs; mechanistic relevance is in its role altering proteasome proteolytic activity—reduces chymotrypsin-like activity and shapes peptide repertoire for thymic selection
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteasome subunit beta type-11 (PSMB11).